Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Test Your Knowledge Previous | All Articles This Week | Next
This article originally posted 14 September, 2012 and appeared in  GLP-1 Receptor Agonist TherapyIssue 643

SPECIAL GLP-1 Test Your Knowledgee #643: Which of the following are true regarding these two classes of medications?

Lilly is a 45-year-old female, 5'3", 175 lbs, who was diagnosed with type 2 diabetes two years ago.

Advertisement

She is currently taking Metformin 1000 mg twice daily and Glimepiride 4 mg daily. She has made several lifestyle changes after the diagnosis but still has trouble reaching her goal weight and her glycosylated hemoglobin (HbA1c) only minimally decreased to 7.5%. Her doctor decides to add a third agent to her regimen. The doctor is thinking about adding either GLP-1 agonist or a DPP-IV inhibitor to her regimen.

Which of the following are true regarding these two classes of medications? 

(I) GLP-1 agonists have less GI adverse effects compared to DPP-IV inhibitors
(II) DPP-IV inhibitors are associated with more weight loss compared to GLP-1 agonists
(III) GLP-1 agonists provide better cardioprotection compared to DPP-IV inhibitors

(A) I only

(B) III only

(C) I and II only

(D) II and III only

(E) I, II, and III 

For the correct answer, please click here.

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 14 September, 2012 and appeared in  GLP-1 Receptor Agonist TherapyIssue 643

Past five issues: Diabetes Clinical Mastery Series Issue 137 | Issue 677 | SGLT2 Special Edition Issue 2 | Diabetes Clinical Mastery Series Issue 136 | Issue 676 |

 
Diabetes In Control Advertisers
 
Cast Your Vote
Should a person newly diagnosed with prediabetes be treated with medication along with lifestyle changes?

Navigate Diabetes In Control
CME/CE of the Week
Derek LeRoith, MD

Category: General Diabetes
Credits: .5
Search Articles On Diabetes In Control